New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review

Abstract

Background Vaccination has been promoted to control viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of psoriasis, an immune-mediated inflammatory disease, were reported following COVID-19 vaccination. However, a comprehensive review examining the association between COVID-19 vaccination and the occurrence or exacerbation of psoriasis has yet to be performed. Objective The aim of this systematic review is to investigate the demographics, clinical variables, and outcomes associated with psoriasis following COVID-19 vaccination. Methods A systematic literature search was conducted using the PubMed, Embase, Web of Science, and Cochrane databases from database inception to April 25, 2022. The review included studies with relevant terms, including ‘psoriasis,’ ‘psoriasis vulgaris,’ ‘guttate psoriasis,’ ‘pustular psoriasis,’ ‘palmoplantar pustulosis,’ ‘psoriatic erythroderma,’ ‘psoriatic arthritis,’ ‘COVID-19,’ and ‘vaccine.’ We included all studies reporting at least one patient who developed new-onset psoriasis or experienced a psoriasis flare following at least one dose of any COVID-19 vaccine. A flare was defined as the worsening of disease conditions after vaccination according to the study by Gregoire et al. The appraisal tool described by Murad et al. was used to assess the quality of case reports and series, whereas the National Institute of Health quality assessment tool was used to assess observational studies. Results The initial search yielded 367 results, including 7 studies reporting new-onset psoriasis, 32 studies reporting psoriasis flares, and 4 studies reporting both. The most commonly observed psoriasis subtype was plaque-type psoriasis. mRNA vaccines, including those produced by Moderna and BioNTech/Pfizer, were frequently associated with subsequent psoriasis episodes. First, second, and third vaccine doses were associated with psoriasis incidents, with the second dose most frequently associated with psoriasis flares. Delayed onset was observed, ranging from 2 to 21 days in the new-onset group and from 1 to 90 days in the flare group. Most patients experienced favorable outcomes, with improvement or resolution occurring within 3 days to 4 months. Conclusions Both new-onset psoriasis and psoriasis flares were reported as cutaneous adverse events following COVID-19 vaccination. Psoriatic patients may require regular follow-up before and after COVID-19 vaccination. Trial Registration Review registration number PROSPERO database: CRD42022304157. Supplementary Information The online version contains supplementary material available at 10.1007/s40257-022-00721-z.

COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

“…Similar timing has also been observed in the occurrence of other autoimmune skin diseases following COVID‐19 vaccination. Wu et al 39 conducted a systematic review and reported that the majority of patients with new‐onset psoriasis presented 1 to 2 weeks (range, 2–21 days) following vaccination. Ganjei et al 40 reviewed 19 cases of alopecia areata occurrence after COVID‐19 vaccination, and 11 cases had a reported onset within 2 weeks (range, a few days to 4 months).…”

Two‐year impact of COVID‐19 pandemic on hospitalized patients with skin diseases in China

“…In the pandemic group, the relative stability of the absolute number of patients with keratinolytic carcinoma and the smaller number of total hospitalized patients with skin disease contribute to the higher proportion of this disease. With regard to psoriasis, one possible reason for the higher proportion of this skin condition in the pandemic group is that most people in China have been vaccinated against COVID‐19, which can lead to new onset and aggravation of psoriasis 13,14 . The reasons for the increased proportion of dermatitis in the pandemic group could be twofold.…”

Factors associated with worsened clinical symptoms of psoriasis and disease-related quality of life during the COVID-19 lockdown: A cross-sectional study

“…Vaccination is not common trigger for psoriasis symptoms exacerbation ( 59 ), but there are some reports of psoriasis symptoms worsening after vaccination for influenza, pneumococcal pneumonia, and yellow fever ( 60 ). New onset and exacerbation of psoriasis were reported in the systemic review and case series documenting new diagnosis of psoriasis or psoriasis exacerbation after at least one dose of any COVID-19 vaccine ( 61 , 62 ). However, COVID-19 vaccination in Lithuania has actively started in Jan 2021 and lasted until the end of this study (Apr 2021) with 24.7% of Lithuanian population receiving the first dose of the vaccine.…”